-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Yaojie Ankang-B (02617.HK) announced that the phase II clinical trial of the company's product TT-00973 tablets combined with vometinib mesylate to treat locally advanced or metastatic non-small cell lung cancer with EGFR sensitive mutations was approved by the National Drug Administration (NMPA) on July 10, 2026.

Zhitongcaijing·07/10/2026 14:25:06
Listen to the news
According to Zhitong Finance App, Yaojie Ankang-B (02617.HK) announced that the phase II clinical trial of the company's product TT-00973 tablets combined with vometinib mesylate to treat locally advanced or metastatic non-small cell lung cancer with EGFR sensitive mutations was approved by the National Drug Administration (NMPA) on July 10, 2026.